Civica Infrastructure Inc

• Biocon Biologics will supply Insulin Aspart drug substance to Civica, who will manufacture the final product at their Virginia facility to increase accessibility in the United States. • The partnership aims to address a critical healthcare need, as one in five diabetes patients has rationed insulin due to cost concerns, in a country where 38.4 million people live with diabetes. • The collaboration runs parallel to Biocon Biologics' own Insulin Aspart product currently under FDA review, demonstrating the company's multi-pronged approach to expanding insulin accessibility.